Merck & Co., Inc.
149 $
-0.06% day
Shares in Merck & Co., the New Jersey drugmaker known as MSD outside North America. Its cancer immunotherapy Keytruda is among the world's best-selling drugs, so the stock trades on that franchise and on what replaces it once its patents lapse.
Sep 28 · 148.69 $ · +0.6% vs the window’s open
the numbers20
| when | value | change |
|---|---|---|
| Aug 31 | 147.76 $ | |
| Sep 1 | 149.86 $ | +1.4% |
| Sep 2 | 151.64 $ | +1.2% |
| Sep 3high | 152.34 $ | +0.5% |
| Sep 4 | 150.33 $ | −1.3% |
| Sep 8 | 148.46 $ | −1.2% |
| Sep 9 | 147.53 $ | −0.6% |
| Sep 10 | 144.71 $ | −1.9% |
| Sep 11 | 143.93 $ | −0.5% |
| Sep 14 | 144.85 $ | +0.6% |
| Sep 15low | 143.79 $ | −0.7% |
| Sep 16 | 144.91 $ | +0.8% |
| Sep 17 | 147.15 $ | +1.5% |
| Sep 18 | 146.87 $ | −0.2% |
| Sep 21 | 149.50 $ | +1.8% |
| Sep 22 | 150.91 $ | +0.9% |
| Sep 23 | 148.08 $ | −1.9% |
| Sep 24 | 147.98 $ | −0.1% |
| Sep 25 | 148.78 $ | +0.5% |
| Sep 28latest | 148.69 $ | −0.1% |
Lately
The only Merck news of the fortnight came from Rahway at the very end of it: the company quietly stopped supplying a last-resort antibiotic used against drug-resistant infections. It arrived after both the stock's peak and its trough, so it does not account for either.